Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Detoxifying 'super fungi' may recover critical minerals
Training centre opens to improve alloy lifecycle
Water utilities know where AI fits — but can the foundations carry it?
FIFA World Cup to generate 156 tonnes of plastic waste
Collaboration provides NZ's largest smart water meter upgrade
Deakin University launches metal resources research centre
Dragos introduces OT-native cybersecurity AI
Construction begins on south-west WA advanced manufacturing hub
Newcastle carbon capture plant opens
Accenture acquires Dragos and increases OT cybersecurity offering
Testing beef trim sampling cloths for Escherichia coli O157:H7, STEC, and Salmonella species with harmonised enrichments
Breaking the biofilm shield that harbours foodborne pathogens
Second cell-cultured food under assessment by FSANZ
Indigenous food culture and responsible seafood celebrated
Shaking up whey protein manufacturing technique